Rheumatology Network Newsletter

To view this email as a web page, click here.

EULAR 2019 Reports

Cancer and TNFi Link in Psoriatic Arthritis Disproven

The overall risk of cancer in psoriatic arthritis patients who are treated with TNF inhibitors doesn’t appear to be linked to their treatment, according to a study presented EULAR this weekend.

Lupus Nephritis Remission with Cyclosporine, Mycophenolate Mofetil, Azathioprine

Lupus nephritis remained in remission for over 10 years in a group of patients who were treated with cyclosporine A, mycophenolate mofetil or azathioprine, shows a study presented at the European Congress of Rheumatology (EULAR) annual meeting this weekend in Madrid.

Combo Treatment Reduces Uric Acid and Albumin in Kidney/Gout Patients

An intensive treatment strategy that combines ebuxostat (Uloric, Takeda) and the novel verinurad, significantly reduced hyperuricemia and albuminuria in patients with type 2 diabetes patients.

Phase 2B Trial of Tildrakizumab Shows Promise in Psoriatic Arthritis

A 24-week trial of tildrakizumab to treat the skin and joint conditions associated with psoriatic arthritis shows promise as a possible new treatment, shows a study presented at EULAR.

Stimulating Vagus Nerve Proves to Reduce Rheumatoid Arthritis Symptoms

A pilot study presented this weekend at EULAR suggests that electro stimulation of the vagus nerve reduces rheumatoid arthritis symptoms.

High BMI Associated with Psoriatic Arthritis and Rheumatoid Arthritis

Three studies presented this weekend at EULAR in Madrid suggest that being overweight or obese can heighten the severity or arthritic disease.

This is a post-only, outbound email. Please do not reply to this email as we will be unable to respond to your reply. Please use the links provided if you have questions or concerns regarding this email or your subscription.